Stemolecule SB431542

Catalog 04-0010-10
04-0010
Size 10 mg (Cat. No. 04-0010-10)
5 mg (Cat. No. 04-0010)
Price
$99.00
$99.00
Availability In stock
Catalog
04-0010-base

Product Overview

SB431542 is an inhibitor of the transforming growth factor-beta 1 (TGF-β1) activin receptor-like kinases (ALKs). It is a selective and potent inhibitor of ALK-4, -5 and -7. SB431542 inhibits endogenous activin and TGF-β signaling without affecting more divergent BMP signaling utilizing ALK-1, -2, -3, and -61,2. SB431542 stimulates proliferation, differentiation, and sheet formation of endothelial cells derived from embryonic stem cells3.

Also available: Stemolecule SB431542 in Solution (04-0010-05)

Product Specifications

Product Name
Stemolecule SB431542
Catalog Number
04-0010-base
Size
10 mg (Cat. No. 04-0010-10)
5 mg (Cat. No. 04-0010)
Alternate Name(s)
4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
Chemical Formula
C22H16N4O3
Molecular Weight
384.4
CAS Number
301836-41-9 (anhydrous)
Purity
Greater than 98% by HPLC analysis
Formulation
White solid
Solubility
Reconstitute in DMSO to the desired concentration. For reconstitution instructions please reference product specifications sheet.
Storage and Stability
Store powder at 4 °C protected from light.
Information about the stability of Stemolecules in solution is largely not available. As a general guideline, we recommend that stock solution be freshly made and stored in aliquots at -20 °C, protected from light. The effect of storage of stock solutions should be verified for each application.
Quality Control
The purity of SB431542 was determined by HPLC analysis. The accurate mass was determined by mass spectrometry. Cellular toxicity of SB431542 was tested on mouse embryonic stem cells.


References

  1. Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H.K., Imamura, T., Miyazono, K., Miyazawa, K. (2003) SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 63: 7791-7798.
  2. Laping, N.J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J.F., and Olson, B.A. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64.
  3. Inman, G.J., Nicolás, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, A.D., Laping, N.J., and Hill, C.S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
  4. Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., Nishikawa, S., and Miyazono, K. (2003) TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol. 163: 1303-1311.

Additional Publications

Product Specifications

Product Name
Stemolecule SB431542
Catalog Number
04-0010-base
Size
10 mg (Cat. No. 04-0010-10)
5 mg (Cat. No. 04-0010)
Alternate Name(s)
4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
Chemical Formula
C22H16N4O3
Molecular Weight
384.4
CAS Number
301836-41-9 (anhydrous)
Purity
Greater than 98% by HPLC analysis
Formulation
White solid
Solubility
Reconstitute in DMSO to the desired concentration. For reconstitution instructions please reference product specifications sheet.
Storage and Stability
Store powder at 4 °C protected from light.
Information about the stability of Stemolecules in solution is largely not available. As a general guideline, we recommend that stock solution be freshly made and stored in aliquots at -20 °C, protected from light. The effect of storage of stock solutions should be verified for each application.
Quality Control
The purity of SB431542 was determined by HPLC analysis. The accurate mass was determined by mass spectrometry. Cellular toxicity of SB431542 was tested on mouse embryonic stem cells.

References

  1. Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H.K., Imamura, T., Miyazono, K., Miyazawa, K. (2003) SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 63: 7791-7798.
  2. Laping, N.J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J.F., and Olson, B.A. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64.
  3. Inman, G.J., Nicolás, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, A.D., Laping, N.J., and Hill, C.S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
  4. Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., Nishikawa, S., and Miyazono, K. (2003) TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol. 163: 1303-1311.

Additional Publications